bioAffinity Technologies Raises $4M in At-the-Market Offering to Fuel Lung Cancer Test Expansion
Event summary
- bioAffinity Technologies closed a $4M registered direct offering of common stock at $6.122 per share
- Concurrent private placement included warrants for up to 980,072 shares at the same exercise price
- Proceeds will support working capital and sales growth for CyPath® Lung, its noninvasive lung cancer test
- Offering conducted under Nasdaq at-the-market rules and SEC Form S-3 registration
- WallachBeth Capital served as sole placement agent for the transaction
The big picture
This $4M raise positions bioAffinity to scale its noninvasive lung cancer diagnostic amid growing demand for early detection solutions. The at-the-market structure suggests strategic flexibility in capital deployment, while the focus on working capital highlights near-term commercialization priorities. The transaction comes as biotech investors increasingly scrutinize diagnostic companies' ability to demonstrate clinical utility and reimbursement pathways.
What we're watching
- Commercial Execution
- How effectively bioAffinity can convert this capital into CyPath Lung sales growth
- Market Positioning
- Whether the company can differentiate CyPath Lung in the competitive lung cancer diagnostics space
- Regulatory Dynamics
- The pace at which CLIA oversight might evolve and impact LDT offerings like CyPath Lung
Related topics
